Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma.
暂无分享,去创建一个
[1] A. Chott,et al. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[3] K. Turetschek,et al. Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. , 2007, Anticancer research.
[4] A. Chott,et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course , 2007, Leukemia.
[5] K. Turetschek,et al. Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma , 2007, Oncology.
[6] K. Turetschek,et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Y. Matsuno,et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] U. Jaeger,et al. High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up , 2005, Clinical Cancer Research.
[9] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[10] S. Pileri,et al. Fludarabine‐containing chemotherapy as frontline treatment of nongastrointestinal mucosa‐associated lymphoid tissue lymphoma , 2004, Cancer.
[11] A. López-Guillermo,et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.
[12] T. Molina,et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. , 2001, Gastroenterology.
[13] A. Chott,et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Ming-Qing Du,et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.
[15] F. Cavalli,et al. The gastric marginal zone B-cell lymphoma of MALT type. , 2000, Blood.
[16] S. Pileri,et al. From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Stolte,et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. , 1997, Gastroenterology.
[18] G. Salles,et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. López-Guillermo,et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.